RISK

Trading carries substantial risk of loss. Prop evaluation fees are typically non-refundable and the majority of traders do not pass first attempts. This comparison is for informational purposes only and does not constitute financial advice. Read full risk warning

HEAD-TO-HEAD COMPARISON · 2026

LiquidityX vs Next Step Funded

Side-by-side comparison of trust scores, profit splits, payout speed, and real trader reviews. Independent data — no sponsored rankings.

LQDX

LiquidityX

EST. 2026

NXSF

Next Step Funded

LIQUIDITYX

METRIC

NEXT STEP FUNDED

0/100TIE

TRUST SCORE

TIE0/100

0/5TIE

RATING

TIE0/5

—

PROFIT SPLIT

—

MAX FUNDING

—

MIN COST

—

PAYOUT DAYS

—

PASS RATE

—

0TIE

REVIEW COUNT

TIE0

LIQUIDITYX DETAILS

STEPS: -phase

NEXT STEP FUNDED DETAILS

STEPS: -phase

LiquidityX PROS

+Placeholder pro — no data provided beyond founding year; no metrics to evaluate
+Placeholder pro — no data provided beyond founding year; no metrics to evaluate
+Placeholder pro — no data provided beyond founding year; no metrics to evaluate
+Placeholder pro — no data provided beyond founding year; no metrics to evaluate

LiquidityX CONS

−Founded in 2026, meaning this firm does not yet exist at time of writing
−A future founding date raises serious concerns about legitimacy and operational status
−No trading metrics are available to compare against any industry averages

Next Step Funded PROS

+No data is available to identify any pros for Next Step Funded at this time.
+No platform or market information is provided to assess trading conditions.
+No funding or cost data is available to compare against industry benchmarks.
+No profit split or payout data exists to evaluate trader compensation.

Next Step Funded CONS

−No data whatsoever is available for Next Step Funded, making any evaluation impossible.
−Complete absence of key metrics such as drawdown, profit split, and funding is a significant transparency concern.
−Traders have no basis for comparison against industry averages with zero data disclosed.

PROPDNA VERDICT